Synthetic Biologics Inc. said Jeff Riley resigned as CEO and board director for personal reasons.
Synthetic's CFO, Steve Shallcross, will take over CEO duties on an interim basis.
Synthetic Biologics CFO to lead company on interim basis
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Synthetic Biologics Inc. said Jeff Riley resigned as CEO and board director for personal reasons.
Synthetic's CFO, Steve Shallcross, will take over CEO duties on an interim basis.